Current Setup & Catalysts
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Current Setup in One Page
The stock closed at $0.42 on 5 June 2026 — round-tripping the entire 2025 rally back to mid-IPO levels. Three watchpoints dominate: (i) whether the FY27 "low double-digit CC, 24–25% adj EBITDA" guide proves as conservative as FY26's did, (ii) when EQT clears the next slug of its 100%-pledged 50.95% residual stake, and (iii) whether the ESOS 2026 postal ballot (launched 31 May 2026) sets a credible strike and performance hurdle for management equity issued during the controlling-shareholder sell-down. Setup: Mixed. Operational delivery is the cleanest credibility track on the Indian mid-cap BPM tape (FY26 guide raised three quarters in a row, FY27 guide already deemed sandbagged by sell-side); the tape, the promoter pledge, two CFO transitions in six months, and the soft FY27 starting guide are all live drags. The first real underwriting update is the Q1 FY27 print, due in the last week of July 2026.
Recent setup rating
Hard-dated events next 6m
High-impact catalysts next 6m
Days to next hard date
Last close ($)
YTD return (%)
Most recent strategic event
Next hard-dated event
The single most important near-term event is the Q1 FY27 print in late July 2026. Not because one quarter resolves the long-term thesis, but because it is the first read on whether the conservative FY27 guide (low double-digit CC, 24–25% adj EBITDA) is sandbagging or signal. The bear's primary trigger — sub-12% CC growth with sub-22% margin — and the bull's first proof point — beat-and-raise consistent with the FY26 cadence — both resolve at the same data point.
What Changed in the Last 3–6 Months
The narrative arc of the last six months is a single sentence: the market priced the EQT exit, then priced the AI deflation, and is now pricing the conservatism of the FY27 guide as if it were a downgrade — even though management's track record across seven quarters since IPO is twelve "met-or-beat" outcomes against fifteen disclosed promises. What investors used to worry about (concentration, GenAI cannibalisation as a binary threat) has been reframed by management with credible numbers — top-3 fell below 60%, AI deployed across 8 clients in 18 use cases. What they worry about now is unresolved: the Synchrony revenue line is still narrative-only, the BroadPath cross-sell stalled at AEP, the next EQT OFS clearing price is unknown, and the FY27 margin band implicitly walks back the FX tailwind that built the 24.5% print. The Q1 FY27 cadence resolves the conservatism question and reframes the rest.
What the Market Is Watching Now
Ranked Catalyst Timeline
The ranking below is decision-value first, chronology second. A high-impact catalyst with a soft date is ranked above a low-impact catalyst on a hard date.
Calendar quality is Medium. Five events have hard dates inside six months (Q1 FY27, ESOS ballot result, AGM, Q2 FY27, AEP/Q3 setup). Three of the highest-impact catalysts have soft dates (next OFS, Synchrony disclosure, Capgemini-WNS Healthcare segment read). The catalyst that would update the thesis most — the first quantified Synchrony number — has the lowest date confidence.
Impact Matrix
The matrix below filters the timeline down to the catalysts that genuinely update durable thesis variables, not just one-quarter noise.
The honest read: three of these five update the long-term thesis, not just the next quarter. The Q1 FY27 print and the AEP cycle are near-term evidence — important but not by themselves underwriting-changing. The Synchrony disclosure, the OFS pricing, and the ESOS structure are the three that move the curve, not just the slope.
Next 90 Days
The 90-day calendar is adequate but not deep: one earnings print, one postal-ballot outcome, one AGM, one peer-read window. The events with the largest decision value — the next EQT OFS, the first quantified Synchrony number, and the next named BroadPath cross-sell — are all outside the 90-day calendar with soft dates. A PM running this name through summer is implicitly underwriting that the Q1 FY27 print holds the FY27 guide tone, that the ESOS result does not surface a strike-pricing controversy, and that the EQT OFS does not arrive before the print. Any one of those breaking is the trigger to revisit position size.
What Would Change the View
Two observable signals would change the investment debate most over the next six months. First, the Q1 FY27 print is the single bilateral data point — beat-and-raise consistent with the FY26 cadence (CC growth 14%+, margin sustaining at 24.5%+, AI cannibalisation contained at 2%) crystallises the bull's "credibility track + scarcity premium + FCF compounder" case and opens the 12-month re-rating window toward $0.53–$0.59; a sub-12% CC, sub-23.5% margin print is the explicit bear primary-trigger configuration and pulls the multiple toward the 15x Indian-BPM-cohort discount. Second, any disclosure that makes Synchrony tangible — a named outcome-based deal beyond the Convey/Simplify alliance, a percent-of-new-ACV number, or a P&L line item in an investor deck — is the single piece of evidence that resolves both the AI-deflation bear case (at the operating-margin line) and the Long-Term Thesis mix-shift driver simultaneously. The two tail signals worth pricing alongside are the next EQT OFS clearing price (calling the structural floor under the stock) and the ESOS 2026 strike-pricing decision (calling management alignment through the anchor-shareholder transition). Everything else on the 90-day calendar — the AGM, the GST demand resolution, the HIRE Act tracker — is texture, not signal.